IL6 mRNA

IL6 mRNA is a ready-to-use messenger RNA (mRNA) encoding interleukin-6 (IL-6), a cytokine involved in acute-phase responses and inflammatory signaling. IL-6 plays a central role in the pathogenesis of rheumatoid arthritis, Crohn’s disease, and various malignancies, making it an important target for IL-6–directed therapies. It is suitable for research on chronic inflammation, tumor-associated inflammation, immune regulation, and mRNA delivery. The transcript is designed for expression in eukaryotic cells. It contains the nucleic acid sequence encoding the 212 amino acid IL6 protein sequence, together with non-coding regulatory elements typically required for efficient translation and stability (5′ untranslated region, 3′ untranslated region, and a 3′ poly(A) tail). The mRNA contains a 5′ Cap 1 structure, and all uridine residues are fully substituted with N1-methyl-pseudouridine (m¹Ψ) to support robust protein expression and to reduce innate immune sensing relative to unmodified mRNA. The mRNA is produced enzymatically by in vitro transcription from a DNA template, followed by capping, polyadenylation, and purification. Promoter sequences used to drive in vitro transcription from the DNA template are not part of the final mRNA product. For research use only (RUO). Not for diagnostic or therapeutic use, and not for human or animal administration.